

## Special Issue

# YAP (Yes-Associated Protein) in Cancer

### Message from the Guest Editors

The Yes-associated protein (YAP) is a highly evolutionarily conserved transcriptional co-factor involved, mainly together with the transcriptional coactivator with PDZ-binding motif (TAZ), in the regulation of various cellular processes, including proliferation, survival, differentiation, and stem cell maintenance. Dysregulation of YAP expression/activity has been frequently observed in cancer, where it plays a pivotal role in both tumor onset and progression. While oncogenic YAP activity has been widely reported, recent data unveiled a tumor suppressor role in specific cellular contexts. Moreover, additional roles of YAP in inflammation and tumor immunity have been described, indicating the protein as a key inducer of tumor microenvironmental changes. This Special Issue will highlight the role of YAP and of its complex regulation in cancer, through both basic and preclinical studies, thus opening new perspectives for targeted therapies.

---

### Guest Editors

Dr. Alessandra Marchetti

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

Dr. Laura Amicone

Department of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185 Roma RM, Italy

---

### Deadline for manuscript submissions

closed (31 March 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/41177](https://mdpi.com/si/41177)

*Cancers*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)